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Diﬀ erences among the coloured, white, black, and other 
South African populations in smoking-attributed mortality 
at ages 35–74 years: a case-control study of 481 640 deaths
Freddy Sitas, Sam Egger, Debbie Bradshaw, Pam Groenewald, Ria Laubscher, Danuta Kielkowski, Richard Peto
Summary
Background The full eventual eﬀ ects of current smoking patterns cannot yet be seen in Africa. In South Africa, 
however, men and women in the coloured (mixed black and white ancestry) population have smoked for many 
decades. We assess mortality from smoking in the coloured, white, and black (African) population groups.
Methods In this case-control study, 481 640 South African notiﬁ cations of death at ages 35–74 years between 1999 and 
2007 yielded information about age, sex, population group, education, smoking 5 years ago (yes or no), and underlying 
disease. Cases were deaths from diseases expected to be aﬀ ected by smoking; controls were deaths from selected 
other diseases, excluding only HIV, cirrhosis, unknown causes, external causes, and mental disorders. Disease-
speciﬁ c case-control comparisons yielded smoking-associated relative risks (RRs; diluted by combining some ex-
smokers with the never-smokers). These RRs, when combined with national mortality rates, yielded smoking-attributed 
mortality rates. Summation yielded RRs and smoking-attributed numbers for overall mortality.
Findings In the coloured population, smoking prevalence was high in both sexes and smokers had about 50% higher 
overall mortality than did otherwise similar non-smokers or ex-smokers (men, RR 1·55, 95% CI 1·43–1·67; women, 
1·49, 1·38–1·60). RRs were similar in the white population (men, 1·37, 1·29–1·46; women, 1·51, 1·40–1·62), but 
lower among Africans (men, 1·17, 1·15–1·19; women, 1·16, 1·13–1·20). If these associations are largely causal, 
smoking-attributed proportions for overall male deaths at ages 35–74 years were 27% (5608/20 767) in the coloured, 
14% (3913/28 951) in the white, and 8% (20 398/264 011) in the African population. For female deaths, these proportions 
were 17% (2728/15 593) in the coloured, 12% (2084/17 899) in the white, and 2% (4038/205 623) in the African 
population. Because national mortality rates were also substantially higher in the coloured than in the white population, 
the hazards from smoking in the coloured population were more than double those in the white population.
Interpretation The highest smoking-attributed mortality rates were in the coloured population and the lowest were in 
Africans. The substantial hazards already seen among coloured South Africans suggest growing hazards in all 
populations in Africa where young adults now smoke.
Funding South African Medical Research Council, UK Medical Research Council, Cancer Research UK, British Heart 
Foundation, New South Wales Cancer Council.
Introduction
In South Africa, about 80% of the population consider 
themselves black (African), 9% white, 9% coloured 
(mixed black and white ancestry), and 2% Asian (mainly 
Indian).1 These apartheid-era groupings remain impor-
tant correlates of mortality2–4 and lifestyle. The coloured 
population has smoked for many years; in 1977, 79% and 
52% of men and women in the coloured population were 
smokers, mostly of ten or more cigarettes per day.5 
Surveys of Africans before 1990 were conducted only in 
white areas;5 subsequent surveys of Africans found lower 
prevalences, lower daily consumption, and older age at 
starting smoking than in the coloured population.6–10 
Despite minor ﬂ uctuations during the 1990s,6 in 1998 
long-term cessation was common only in the white 
population.7 Thus, diﬀ erent population groups are at 
diﬀ erent stages of the tobacco epidemic.11
In the 1990s, South African death certiﬁ cation was 
being reformed. To help to assess separately the eﬀ ects of 
smoking on mortality in each of its diﬀ erent populations, 
in 1998 South Africa became the ﬁ rst (and unfortunately 
remains the only) country to ask during routine death 
notiﬁ cation about smoking history. We aimed to use this 
and other information from the death notiﬁ cation forms 
to help to assess nationwide tobacco-attributed mortality 
in each population group from particular smoking-
related diseases (and, by summation, from all diseases).
Methods
Design
In this case-control study, we compared smoking histories 
of adults dying from the diseases that smoking can aﬀ ect 
(cases) and those dying from selected other diseases 
(controls). Death notiﬁ cation, including cause, is com-
pulsory. Two-thirds of the underlying causes of death 
came from a certifying doctor or autopsy;10 most others 
were from family members. Immediate and antecedent 
causes are entered according to WHO guidelines.12 
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Statistics South Africa then assigns the underlying cause 
its 10th International Classiﬁ cation of Diseases three-
character code (eg, C33–34 for primary lung cancer).12 
During 1998 the notiﬁ cation form was revised 
(appendix pp 3–4) to ask informants: was the deceased a 
smoker ﬁ ve years ago? The four tick-box options are: Yes, 
No, Do not know, Not applicable (minor). The form 
deﬁ nes a smoker as someone who smokes on most days, 
and negative replies to this question group together 
never-smokers and long-term ex-smokers. Informants 
are also asked: do you consider the deceased to have been 
African, Coloured, White, Indian, or Other? (In our 
analyses, we add Indian into Other.) Witwatersrand 
University ethics committee (Johannesburg, South 
Africa) approved the questions in 1995.
The present analyses of an anonymised public dataset 
of notiﬁ cations13 were restricted to deaths at ages 
35–74 years from 1999 (the ﬁ rst year the smoking 
question was included on all death notiﬁ cations) to 2007 
with information about age, year of death, sex, province 
of death, educational grade, marital status, population 
group (African, coloured, white, or other [mostly 
Indian]), and smoking status (yes or no, excluding other 
answers). Restriction to ages 35–74 years was because 
smoking was expected to cause few deaths before age 
35 years, and cause of death information can be 
unreliable in old age (partly because of multiple co-
morbidities). Deaths from Kaposi’s sarcoma, other HIV-
related disease, external causes, cirrhosis, or mental and 
behavioural disorders were excluded from the case-
control analyses because any association with smoking 
could be non-causal. Ill-deﬁ ned and unknown causes 
were also excluded.
For the remaining deaths, our analyses relate the 
under lying cause (case or control) to smoking (yes or no). 
Cases were deaths from 11 groups of diseases that other 
studies have shown could be aﬀ ected by smoking 
(diseases of interest): tuberculosis, chronic obstructive 
pulmonary disease (COPD), other respiratory disease, 
stroke (including hypertensive disease), ischaemic heart 
disease (including degenerative artery disease), other 
cardiovascular disease, myeloid leukaemia, cancer of the 
lung, upper aerodigestive tract (oesophagus, mouth, 
pharynx, larynx, nasal cavity, and sinuses), urinary tract 
or female genital tract, and three conditions in which 
smoking could be protective (Parkinson’s disease, 
ulcerative colitis, and endometrial cancer; appendix p 5). 
Controls were deaths from all other speciﬁ ed diseases.
Statistical analysis
Relative risk (RR) was taken as the case/control 
versus smoker/non-smoker (or ex-smoker) odds ratio, 
See Online for appendix
Figure 1: Prevalence of smoking 5 years before death among the 159 548 controls, by sex, age, and South African population group
0
20
40
60
80
Pr
ev
al
en
ce
 o
f s
m
ok
er
s (
%
)
A Coloured B White
35
–39
40
–4
4
45
–4
9
50
–54
55
–59
60
–6
4
65
–6
9
70
–74
0
20
40
60
80
Pr
ev
al
en
ce
 o
f s
m
ok
er
s (
%
)
Age (years)
C African
35
–39
40
–4
4
45
–4
9
50
–54
55
–59
60
–6
4
65
–6
9
70
–74
Age (years)
D Other
Male
Female72·5 70·5 71·6 69·7
65·4
60·0
55·2
50·4
51·7 51·2 50·8
43·7 43·1 40·5
35·0
25·4
45·3
51·3
53·9 52·7
46·6
40·7
30·6
24·9
24·5
33·0 30·9 29·2 28·3 26·0
22·6
16·6
50·7 52·4 53·0 49·2 47·1
42·1
39·1
33·5
8·1
11·3
14·2 14·1 13·8 12·5 10·9 10·1
60·2
68·2
61·3
58·2
54·8 54·7
44·6
34·1
14·7
11·1 13·8 9·7 9·8 8·2
5·1 4·4
Articles
www.thelancet.com   Vol 382   August 24, 2013 687
calculated by logistic regression adjusted for predeﬁ ned 
confounders: 5-year age group, province, single year of 
death (1999–2007), education (none, primary, higher), 
and marital status (never, widowed or divorced, married 
or living as married). If, for a particular disease, S was 
the total number of deaths in smokers and the excess 
mortality among smokers was actually caused by 
smoking, then the smoking-attributed number of 
deaths could be calculated as S(1 – 1 / RR).14,15 Where the 
smoking-attributed number was positive it could be 
compared with the total number in the whole popu-
lation, yielding the smoking-attributed fraction. Where 
the smoking-attributed number was negative, it and the 
total were still tabulated, but their ratio was not. 
Attributable numbers for groups of diseases (or for 
overall mortality) were from summation of disease-
speciﬁ c numbers.
If, in a particular 10-year age group, M was the national 
mortality rate in 2001 from a particular disease and P the 
control prevalence of smoking, we took the 2001 mortality 
rate in non-smokers and ex-smokers as M / (1 + P[RR – 1]); 
multiplication by RR yielded the rate in smokers.16 From 
these rates we calculated the probabilities that, at 2001 
death rates from this disease (in the hypothetical absence 
of death from other causes), 35-year-old smokers and 
otherwise similar non-smokers (or ex-smokers) would 
die from this disease at various ages from 35 to 64 years 
(ie, cumulative risks).17
South African death certiﬁ cates underestimate nation-
wide numbers of deaths from particular diseases.18 At 
the time of this study, about 16% of deaths had ill-deﬁ ned 
or unknown causes, and many HIV-related deaths were 
attributed to other causes. A previous study therefore 
used models, calibrated to overall mortality, to estimate 
Figure 2: Relative risks of death (smoker vs non-smoker or ex-smoker) in men at ages 35–74 years, by population group and disease
RR=relative risk, adjusted for age, province of death, year of death, education, and marital status. S/NS=numbers of smokers and non-smokers (or ex-smokers) among male cases; the respective 
numbers among male controls were 2531/1464 coloured, 2572/4134 white, 30 699/33 129 African, and 1639/1517 other men.
1 Tuberculosis
RR (95% CI) S/NS RR (95% CI) S/NS
Coloured
White
African
Other
2·80 (2·46–3·19)
2·24 (1·77–2·84)
1·33 (1·30–1·36)
1·72 (1·38–2·14)
 2337/357
 211/111
 29 603/22 226
 309/126
RR, smoker vs non/ex-smoker
2 Chronic obstructive pulmonary disease
Coloured
White
African
Other
2·90 (2·53–3·32)
3·49 (3·14–3·89)
1·69 (1·63–1·76)
2·58 (2·17–3·07)
 1752/350
 1327/688
 7691/5221
 570/217
3 Other respiratory
Coloured
White
African
Other
1·99 (1·68–2·34)
1·60 (1·40–1·83)
1·26 (1·22–1·29)
1·58 (1·29–1·92)
 828/212
 515/502
 19 701/15 503
 314/175
4 Stroke
Coloured
White
African
Other
1·68 (1·48–1·90)
1·62 (1·44–1·82)
1·09 (1·05–1·12)
1·38 (1·19–1·60)
 1247/482
 725/770
 9390/10 780
 564/407
5 Ischaemic heart disease
Coloured
White
African
Other
1·72 (1·52–1·94)
1·67 (1·56–1·80)
1·28 (1·20–1·35)
1·44 (1·29–1·60)
 1468/550
 2907/2833
 2544/2542
 1450/940
6 Other cardiovascular
Coloured
White
African
Other
1·25 (1·07–1·47)
1·81 (1·61–2·04)
1·20 (1·15–1·24)
1·34 (1·14–1·57)
 621/278
 713/671
 6773/6452
 440/327
7 Lung cancer
Coloured
White
African
Other
4·40 (3·64–5·32)
3·46 (3·05–3·92)
3·30 (3·01–3·62)
3·62 (2·76–4·75)
 973/146
 892/463
 1782/677
 268/73
8 Upper aerodigestive cancer
Coloured
White
African
Other
4·00 (3·08–5·19)
2·53 (2·09–3·07)
2·62 (2·45–2·80)
2·53 (1·67–3·84)
 480/71
 299/188
 3150/1443
 81/32
9 Stomach, liver, pancreas cancer
Coloured
White
African
Other
1·75 (1·44–2·11)
1·27 (1·09–1·47)
1·34 (1·23–1·46)
1·36 (1·04–1·78)
 452/173
 366/505
 1210/1147
 140/97
10 Myeloid leukaemia, urinary cancer
Coloured
White
African
Other
1·08 (0·70–1·67)
1·10 (0·88–1·37)
1·11 (0·88–1·41)
1·00 (0·60–1·66)
 54/34
 145/232
 136/163
 31/30
11 Parkinson’s disease, ulcerative colitis
Coloured
White
African
Other
0·64 (0·24–1·69)
0·42 (0·23–0·76)
0·73 (0·40–1·33)
0·38 (0·15–0·94)
 7/10
 13/72
 16/33
 6/20
Total (1–11): All diseases of interest
Coloured
White
African
Other
2·22 (2·05–2·40)
1·93 (1·82–2·05)
1·33 (1·31–1·36)
1·60 (1·47–1·75)
 10 219/2663
 8113/7035
 81 996/66187
 4173/2444
10 2 3 4 5
RR, smoker vs non/ex-smoker
10 2 3 4 5
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numbers of deaths in 2000 by selected causes, 10-year 
age groups and sex.3,19 Treating these estimates as correct, 
we adjusted our numbers of deaths by cause, 10-year age 
group and sex to match them. We then calculated annual 
numbers of smoking-attributed deaths by multiplying 
these adjusted numbers by the smoking-attributed frac-
tions (appendix p 6).
Sensitivity analyses compared people with and without 
missing data, or included records excluded for missing 
information (without or with multiple imputation20 of 
missing values; appendix pp 15–18). Other sensitivity 
ana lyses were restricted to physician-assigned or 
autopsy-assigned causes, or examined the eﬀ ects of 
further restricting the control disease categories 
(appendix pp 19–20). Statistical tests and two-sided 
95% CIs were based on changes in log-likelihood. All 
analyses used Stata 11.0.
Role of the funding sources
Study sponsors had no role in design, data collection, 
analysis, interpretation, or reporting. The Australian 
authors (FS and SE) had full access to all data, and all 
authors had full responsibility for the decision to submit 
for publication.
Results
2 070 044 deaths from a known underlying cause at ages 
35–74 years were notiﬁ ed during 1999–2007. Of these, 
information was almost complete about age, year, sex, 
and province, was mostly complete about marital status 
and population group, but was often missing 
for education or smoking. 573 322 of the deaths 
had information about all these variables, and of 
these 91 682 were from HIV, cirrhosis, external 
causes, or mental and behavioural disorders, leaving 
Figure 3: Relative risks of death (smoker vs non-smoker or ex-smoker) in women at ages 35–74 years, by population group and disease
RR=relative risk, adjusted for age, province of death, year of death, education, and marital status. S/NS=numbers of smokers and non-smokers (or ex-smokers) among female cases; the respective 
numbers among female controls were 1873/2696 coloured, 1500/4656 white, 7683/59 744 African, and 294/3416 other women.
1 Tuberculosis
RR (95% CI) S/NS RR (95% CI) S/NS
Coloured
White
African
Other
2·59 (2·26–2·96)
1·51 (1·09–2·10)
1·37 (1·31–1·43)
2·50 (1·72–3·63)
 950/407
 59/103
 4300/25736
 40/147
RR, smoker vs non/ex-smoker
2 Chronic obstructive pulmonary disease
Coloured
White
African
Other
3·23 (2·82–3·70)
4·16 (3·72–4·66)
1·98 (1·86–2·11)
2·74 (1·97–3·80)
 878/381
 962/773
 1584/5533
 52/218
3 Other respiratory
Coloured
White
African
Other
1·52 (1·30–1·78)
1·60 (1·35–1·89)
1·26 (1·21–1·31)
0·88 (0·55–1·39)
 417/348
 243/473
 4046/23810
 21/252
4 Stroke
Coloured
White
African
Other
1·55 (1·39–1·73)
1·58 (1·39–1·80)
1·07 (1·02–1·12)
1·62 (1·25–2·09)
 985/1059
 439/939
 3199/22222
 89/736
5 Ischaemic heart disease
Coloured
White
African
Other
1·71 (1·50–1·95)
2·27 (2·04–2·53)
1·19 (1·08–1·32)
2·00 (1·60–2·50)
 614/615
 841/1253
 509/3436
 130/957
6 Other cardiovascular
Coloured
White
African
Other
1·74 (1·50–2·01)
1·67 (1·44–1·94)
1·18 (1·11–1·25)
1·37 (1·01–1·85)
 485/432
 313/629
 1915/11325
 56/513
7 Lung cancer
Coloured
White
African
Other
4·04 (3·30–4·95)
4·50 (3·86–5·24)
4·13 (3·48–4·89)
4·83 (3·05–7·65)
 384/147
 481/352
 227/386
 29/64
8 Upper aerodigestive cancer
Coloured
White
African
Other
3·53 (2·56–4·85)
2·77 (2·05–3·74)
2·50 (2·26–2·78)
1·10 (0·58–2·08)
 141/56
 83/98
 576/1583
 11/97
9 Stomach, liver, pancreas cancer
Coloured
White
African
Other
1·72 (1·39–2·13)
1·22 (1·01–1·47)
1·36 (1·18–1·57)
1·50 (0·93–2·42)
 191/189
 169/450
 234/1289
 21/144
10 Myeloid leukaemia, urinary and cervix cancer
Coloured
White
African
Other
1·68 (1·40–2·02)
1·42 (1·13–1·77)
1·18 (1·09–1·29)
0·62 (0·36–1·05)
 303/243
 126/262
 721/4210
 16/155
11 Parkinson’s disease, ulcerative colitis, endometrial cancer
Coloured
White
African
Other
0·50 (0·24–1·06)
0·50 (0·26–0·95)
0·79 (0·50–1·23)
0·05 (0·01–0·33)
 9/30
 11/76
 22/210
 1/41
Total (1–11): All diseases of interest
Coloured
White
African
Other
2·04 (1·90–2·19)
2·27 (2·11–2·44)
1·30 (1·27–1·34)
1·56 (1·34–1·82)
 5357/3907
 3727/5408
 17 333/99740
 466/3324
10 2 3 4 5
RR, smoker vs non/ex-smoker
10 2 3 4 5
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481 640 deaths for our main analyses (322 092 cases, 
159 548 controls; appendix p 5).
Control smoking prevalences were higher in the 
coloured than in any other population group (ﬁ gure 1; 
appendix p 6). Within each group, the prevalences 
matched closely those in the nationwide Demographic 
and Health Survey7 (SADHS; appendix p 7; other case 
and control characteristics are shown on appendix p 8). 
The excess mortality per smoker was also substantial 
in the coloured population. For men, this population 
had the highest smoker versus non-smoker (or ex-
smoker) RRs for the cancer (and most other disease) 
groupings for which previous evidence had suggested 
smoking is harmful (ﬁ gure 2). For women, the coloured 
population also had increased risks of death for most of 
these disease groupings (ﬁ gure 3).
Tables 1 and 2 show, for each population group, the 
absolute numbers of smoking-attributed deaths from 
each of these 11 disease groupings (taking the excess 
mortality from diseases that can be caused by smoking to 
be largely or wholly due to smoking), from control 
diseases, from other known causes (none attributed to 
smoking) and, by summation, from all known causes, 
yielding RRs. The attributed fractions depend not only 
on the RRs, but also on the prevalence of smoking, which 
was higher in the coloured population than in other 
population groups. Hence, for most diseases adversely 
aﬀ ected by smoking the smoking-attributed fraction was 
much greater for the coloured than for the white or 
African population. Diseases that other studies had 
suggested could be reduced by smoking (Parkinson’s 
disease, ulcerative colitis, and endometrial cancer) were 
also inversely related to smoking in this study. The 
number of such deaths avoided was, however, only 0·2% 
(85 vs 40 507) of the total caused by smoking.
For the aggregate of all known causes of death, the 
smoking-attributed fractions were 27% (5608/20 767) in 
the coloured male, 14% (3913/28 951) in the white male, 
8% (20 398/264 011) in the African male, 17% (2728/15 593) 
in the coloured female, 12% (2084/17 899) in the white 
female, and 2% (4038/205 623 in the African female 
population (tables 1 and 2). Thus, the smoking-attributed 
fraction of all deaths was more than twice as great in 
the coloured as in the white population. Nevertheless, 
because of diﬀ ering population sizes African men 
already account for more than half the smoking-attri-
buted deaths in South Africa, despite their as-yet 
relatively low smoking-attributed fraction.
From these totals and the prevalence of smoking we 
were able to estimate the smoking-attributed RR for all 
known causes (ignoring any under-representation of 
deaths from particular underlying causes). For men, 
Coloured White African Other
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Causes of death in men aged 35–74 years
1 Tuberculosis 86·7% 1502/2694 (55·8%) 65·5% 117/322 (36·3%) 57·1% 7302/51 829 (14·1%) 71·0% 129/435 (29·7%)
2 COPD 83·3% 1147/2102 (54·6%) 65·9% 947/2015 (47·0%) 59·6% 3151/12 912 (24·4%) 72·4% 349/787 (44·3%)
3 Other respiratory 79·6% 411/1040 (39·5%) 50·6% 194/1017 (19·1%) 56·0% 4043/35 204 (11·5%) 64·2% 115/489 (23·5%)
4 Stroke 72·1% 503/1729 (29·1%) 48·5% 277/1495 (18·5%) 46·6% 741/20 170 (3·7%) 58·1% 155/971 (16·0%)
5 Ischaemic heart disease 72·7% 614/2018 (30·4%) 50·6% 1171/5740 (20·4%) 50·0% 549/5086 (10·8%) 60·7% 441/2390 (18·5%)
6 Other cardiovascular 69·1% 126/899 (14·0%) 51·5% 320/1384 (23·1%) 51·2% 1107/13 225 (8·4%) 57·4% 111/767 (14·5%)
7 Lung cancer 87·0% 752/1119 (67·2%) 65·8% 634/1355 (46·8%) 72·5% 1242/2459 (50·5%) 78·6% 194/341 (56·9%)
8 Upper aerodigestive cancer 87·1% 360/551 (65·3%) 61·4% 181/487 (37·2%) 68·6% 1949/4593 (42·4%) 71·7% 49/113 (43·4%)
9 Stomach, liver, pancreas cancer 72·3% 193/625 (30·9%) 42·0% 77/871 (8·8%) 51·3% 306/2357 (13·0%) 59·1% 37/237 (15·6%)
10 Myeloid leukaemia, urinary cancer 61·4% 4/88 (4·5%) 38·5% 13/377 (3·4%) 45·5% 14/299 (4·7%) 50·8% 0/61
11 Parkinson’s disease, ulcerative colitis 41·2% −4/17 15·3% −18/85 32·7% −6/49 23·1% −10/26
Subtotal (1–11): all smoking-related 
diseases of interest
79·3% 5608/12 882 (43·5%) 53·6% 3913/15 148 (25·8%) 55·3% 20 398/148 183 (13·8%) 63·1% 1570/6617 (23·7%)
12 Control diseases 63·4% 0/3995 38·3% 0/6707 48·1% 0/63828 51·9% 0/3156
13 All other known causes† 79·2% 0/3890 52·8% 0/7096 53·5% 0/52000 63·7% 0/2516
Total (1–13): all known causes 76·2% 5608/20 767 (27·0%) 49·8% 3913/28 951 (13·5%) 53·2% 20 398/264 011 (7·7%) 60·3% 1570/12 289 (12·8%)
Inferred relative risk (95% CI)‡ ·· 1·55 (1·43–1·67) ·· 1·37 (1·29–1·46) ·· 1·17 (1·15–1·19) ·· 1·27 (1·16–1·38)
All study deaths in 1999–2007 at ages 35–74 years with full data for underlying cause, smoking, and other factors. Smoking-attributed numbers might be underestimated, because non-smoking reference category 
included both never-smokers and ex-smokers. Numbers of smoking-attributed deaths were calculated separately for each age group, then summed over the age range 35–74 years. All-cause total excluded deaths 
from unknown cause (or with any missing data, because analyses were adjusted for province, age, year of death, education, and marital status). *Smoking-attributed fraction (%, from smoking-attributed number/
total number). †Cirrhosis, mental and behavioural disorders, HIV-related disease, and external causes; none of these deaths were attributed to smoking. ‡Relative risk for total deaths from a known cause within the 
study population, back-calculated from the smoking-attributed fraction; if the smoking-attributed fractions for particular causes in the study population are applied to nationwide burden-of-disease estimates of 
the annual numbers of deaths from those causes and then summed to estimate total nationwide numbers of tobacco-attributed deaths (appendix p 9), this could slightly change the smoking-attributed fraction, 
and hence the back-calculated relative risk, for all-cause mortality. 
Table 1: Male deaths attributed to smoking and total male deaths in the study, by population group and disease category
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this overall RR was higher for the coloured population 
(1·55, 1·43–1·67) than for the white (1·37, 1·29–1·46), 
African (1·17, 1·15–1·19), or other population groups 
(1·27, 1·16–1·38; table 1). For women, this overall RR 
was similar for the coloured (1·49, 1·38–1·60) and 
white populations (1·51, 1·40–1·62), but lower for the 
African (1·16, 1·13–1·20) and other population groups 
(1·25, 1·07–1·46; table 2).
Figure 4 combines these RRs for overall mortality and 
the control smoking prevalences with independent 
estimates of overall national mortality rates to estimate 
smoker and non-smoker (or ex-smoker) mortality from 
all causes at ages 35–64 years. (Estimates of population-
speciﬁ c national mortality rates at older ages are of 
uncertain reliability.) For both sexes the absolute excess 
risk per smoker was much greater for the coloured than 
for the white or African populations. Taken together with 
the high prevalence rate of smoking in the coloured 
population group (ﬁ gure 1 and SADHS7), the absolute 
excess risk in the population as a whole (current, ex-
smoker, or never-smoker) is more than twice as great for 
the coloured as for the white or African population. For, 
comparing the coloured versus the white population, in 
the coloured population the absolute risk per smoker was 
much greater (men 14·2% vs 7·6%, women 11·0% vs 
7·7% excess risk of death at ages 35–64 years, ﬁ gure 4) 
and the proportion who had smoked was also much 
greater (men 68% vs 47% [1908/2817 vs 1742/3699], 
women 46% vs 28% [1427/3082 vs 976/3438] control 
smoking prevalence at ages 35–64 years, appendix p 7).
 Approximate adjustment for the under-representation 
of particular diseases in our study would marginally 
reduce all-cause RRs for the coloured male (from 1·55 to 
1·45), coloured female (from 1·49 to 1·37), African male 
(from 1·17 to 1·12), and African female (from 1·16 to 1·12) 
populations (appendix p 9). The RRs for the white popul-
ation would be largely unaﬀ ected by such adjustment.
The calculations in ﬁ gure 4 of patterns of smoker and 
non-smoker (or ex-smoker) mortality at ages 35–64 years 
have been repeated for mortality from particular smoking-
related diseases: tuberculosis, COPD, lung cancer, 
ischaemic heart disease, and all diseases of interest (ie, all 
causes of death of the cases; appendix pp 10–14).
Sensitivity analyses (appendix pp 15–20) show the 
demographics were much the same for deaths that were 
included in the case comparison and those that were 
excluded because a data item was missing, and that the 
RRs were little aﬀ ected by: (1) restoration of the 173 985 
Coloured White African Other
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Smoke (% 
of dead)
Smoking-attributed/
total deaths (%)*
Causes of death in women aged 35–74 years
1 Tuberculosis 70·0% 583/1357 (43·0%) 36·4% 20/162 (12·3%) 14·3% 1154/30 036 (3·8%) 21·4% 24/187 (12·8%)
2 COPD 69·7% 606/1259 (48·1%) 55·4% 731/1735 (42·1%) 22·3% 784/7117 (11·0%) 19·3% 33/270 (12·2%)
3 Other respiratory 54·5% 143/765 (18·7%) 33·9% 91/716 (12·7%) 14·5% 832/27 856 (3·0%) 7·7% −3/273
4 Stroke 48·2% 351/2044 (17·2%) 31·9% 162/1378 (11·8%) 12·6% 209/25 421 (0·8%) 10·8% 34/825 (4·1%)
5 Ischaemic heart disease 50·0% 255/1229 (20·7%) 40·2% 471/2094 (22·5%) 12·9% 83/3945 (2·1%) 12·0% 65/1087 (6·0%)
6 Other cardiovascular 52·9% 206/917 (22·5%) 33·2% 126/942 (13·4%) 14·5% 291/13 240 (2·2%) 9·8% 15/569 (2·6%)
7 Lung cancer 72·3% 289/531 (54·4%) 57·7% 374/833 (44·9%) 37·0% 172/613 (28·1%) 31·2% 23/93 (24·7%)
8 Upper aerodigestive cancer 71·6% 101/197 (51·3%) 45·9% 53/181 (29·3%) 26·7% 346/2159 (16·0%) 10·2% 1/108 (0·9%)
9 Stomach, liver, pancreas cancer 50·3% 80/380 (21·1%) 27·3% 30/619 (4·8%) 15·4% 62/1523 (4·1%) 12·7% 7/165 (4·2%)
10 Myeloid leukaemia, urinary cancer,
cervix cancer
55·5% 123/546 (22·5%) 32·5% 37/388 (9·5%) 14·6% 111/4931 (2·3%) 9·4% −10/171
11 Parkinson’s disease, ulcerative colitis, 
endometrial cancer
23·1% −9/39 12·6% −11/87 9·5% −6/232 2·4% −21/42
Subtotal (1–11): all smoking-related diseases 
of interest
57·8% 2728/9264 (29·4%) 40·8% 2084/9135 (22·8%) 14·8% 4038/117 073 (3·4%) 12·3% 168/3790 (4·4%)
12 Control diseases 41·0% 0/4569 24·4% 0/6156 11·4% 0/67 427 7·9% 0/3710
13 All other known causes† 62·8% 0/1760 36·8% 0/2608 16·8% 0/21 123 12·6% 0/689
Total (1–13): all known causes 53·5% 2728/15 593 (17·5%) 34·6% 2084/17 899 (11·6%) 13·9% 4038/205 623 (2·0%) 10·3% 168/8189 (2·1%)
Inferred relative risk (95% CI)‡ ·· 1·49 (1·38–1·60) ·· 1·51 (1·40–1·62) ·· 1·16 (1·13–1·20) ·· 1·25 (1·07–1·46)
All study deaths in 1999–2007 at ages 35–74 years with full data for underlying cause, smoking, and other factors. Smoking-attributed numbers might be underestimated, because non-smoking reference 
category included both never-smokers and ex-smokers. Numbers of smoking-attributed deaths were calculated separately for each age group, then summed over the age range 35–74 years. All-cause total 
excluded deaths from unknown cause (or with any missing data, because analyses were adjusted for province, age, year of death, education, and marital status). *Smoking-attributed fraction (%, from 
smoking-attributed number/total number). †Cirrhosis, mental and behavioural disorders, HIV-related disease, and external causes; none of these deaths were attributed to smoking. ‡Relative risk for total deaths 
from a known cause within the study population, back-calculated from the smoking-attributed fraction; if the smoking-attributed fractions for particular causes in the study population are applied to nationwide 
burden-of-disease estimates of the annual numbers of deaths from those causes and then summed to estimate total nationwide numbers of tobacco-attributed deaths (appendix p 9), this could slightly change 
the smoking-attributed fraction, and hence the back-calculated relative risk, for all-cause mortality.
Table 2: Female deaths attributed to smoking and total female deaths in the study, by population group and disease category
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deaths excluded because of missing data for education or 
marital status, or both; (2) the use of multiple imputation 
to deal with missing data for these and other variables; 
(3) exclusion of any one particular cause from the 
controls; or (4) restriction of analyses to deaths from a 
disease ascertained by autopsy or certiﬁ ed by a doctor.
Discussion
In interpreting the results of this study, attribution to 
smoking of most or all of the excess mortality among 
smokers is reasonable for deaths from diseases that 
studies elsewhere have shown can be caused by smoking 
(ie, made more probable among otherwise similar 
people of the same age).21,22 Overall, much higher 
proportions of the coloured male and female populations 
were smokers than were their white, African, or other 
counterparts, and much higher proportions of the 
coloured population died from smoking. The higher 
smoking-attributed mortality of the male and female 
coloured populations resulted not only from their higher 
prevalences of smoking, but also from their high relative 
risks of death, comparing smokers with non-smokers 
(or ex-smokers) (panel).
The coloured male population had a higher smoker 
versus non-smoker (or ex-smoker) relative risk of death 
from any cause than did the white male population, who 
in turn had a higher relative risk than did the African 
male population. The coloured and white female popu-
lations had essentially the same relative risk as each 
other, which was much higher than that for the African 
female population. 
This pattern of relative risks is sur prising, because in 
the 1998 nationwide SADHS the cigarette consumption 
per smoker was about twice as great in the white as in the 
coloured or African population groups.7 Conversely, 
however, in the age range 45–64 years the proportion of 
ever-daily-smokers who were no longer daily smokers by 
1998 was far greater (slightly more than half) in the white 
than in the other population groups.7 This factor dilutes 
the relative risks for the white population group in two 
ways, because there must have been substantial numbers 
of ex-smokers both among those reported as having been 
smokers 5 years ago and among those not. For, although 
ex-smokers have lower risks than smokers, they have 
higher risks than never-smokers, particularly of lung 
cancer.21,22 (Thus, in recent US prospective studies22 the 
relative risk of 27 comparing smoker vs never-smoker 
lung cancer mortality rates would have been reduced to a 
relative risk of only 6 if the comparison group had instead 
been a mixture of ex-smokers and never-smokers, as in 
the present study.)
Socioeconomic diﬀ erences in health or in health care 
aﬀ ect the absolute death rates in diﬀ erent population 
groups, but do not necessarily aﬀ ect the smoker versus 
non-smoker (or ex-smoker) death rate ratio. Although 
genetic factors might contribute slightly to diﬀ erences 
between smokers in diﬀ erent population groups in their 
susceptibility to lung cancer,23–25 the reported diﬀ erences 
are too slight to aﬀ ect the present ﬁ ndings to any 
material extent.
One other report considered tobacco-attributed mor-
tality by population group in South Africa,26 but it did 
Figure 4: Smoker and non-smoker (or ex-smoker) all-cause mortality at ages 35–64 years, by age, sex, and 
population group
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Systematic review
Although studies in other continents have shown the substantial hazards of smoking, no 
large study of tobacco-attributed mortality in Africa has been reported; conﬁ rming this, a 
recent (Aug 5, 2013) PubMed search with “Africa” AND “smoking OR tobacco” AND 
“death OR mortality” yielded no relevant results. South African cause-of-death 
notiﬁ cation was modiﬁ ed in 1998 to include a yes/no question about smoking 5 years 
earlier. Proportional mortality analyses of the responses assess tobacco-attributed 
mortality, which is much greater in the coloured (mixed black and white) than in the 
other population groups.
Interpretation
The hazards of smoking are already substantial in the coloured population of South Africa, 
foreshadowing major increases in tobacco-attributed mortality in many other African 
populations where young adults now smoke. In many high-income and middle-income 
countries throughout the world that assign underlying causes to substantial numbers of 
deaths, introduction of one simple question during death notiﬁ cation about previous 
smoking would allow the assessment of current levels of tobacco-attributed mortality, 
and, eventually, of the long-term trends in tobacco-attributed mortality.
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Inclusion of one simple yes or no question on death 
notiﬁ cation forms allowed us to show inexpensively that 
much the highest absolute mortality rate from smoking 
is in the coloured population. Additionally, it allowed us 
to undertake the ﬁ rst large study of tobacco-attributed 
mortality in any population in Africa (many decades 
after the link between smoking and lung cancer was 
shown elsewhere29). In future decades, the accumulated 
responses to this question will allow long-term trends in 
tobacco-attributed mortality to be assessed in each 
population group in South Africa. 
In any population in Europe, America, Asia, or Africa 
with reasonably reliable underlying causes of many deaths 
in middle age, a similar question during death notiﬁ cation 
about smoking 5 (or, perhaps better, 10) years ago could 
likewise allow levels of, and long-term trends in, tobacco-
attributed mortality to be monitored at little cost.30,31 (In 
contrast, asking of each death whether that particular death 
had been caused by smoking would not yield useful data.30)
At present in South Africa, the African population has 
lower mortality rates from smoking than their white or 
coloured counterparts. This ﬁ nding might mainly reﬂ ect 
past diﬀ erences in lifelong smoking patterns, in which 
case the hazards among smokers in successive generations 
are likely to increase substantially over time (as generations 
in which the smokers did not consume substantial 
numbers of cigarettes from early adult life are replaced by 
generations in which they did).21,22,32,33 
Hence, for young African smokers in South Africa, and 
throughout Africa, the eventual hazards of continuing to 
smoke might well be about as great as they are among 
the coloured smokers in this study. If so, then for young 
smokers throughout the continent the absolute beneﬁ ts 
of stopping smoking before middle age would be 
substantial, compared with the growing hazards of 
continuing to smoke.
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